Tricida (NASDAQ:TCDA) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
Shares of NASDAQ TCDA opened at $39.70 on Wednesday. The company has a market cap of $1.93 billion, a PE ratio of -8.56 and a beta of 0.85. Tricida has a 12 month low of $19.43 and a 12 month high of $42.80. The company has a debt-to-equity ratio of 0.11, a current ratio of 14.23 and a quick ratio of 14.22. The company has a 50-day simple moving average of $34.56 and a 200-day simple moving average of $34.54.
In related news, Director Robert J. Alpern sold 1,832 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $38.98, for a total value of $71,411.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Wilhelm Stahl sold 1,039 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $38.98, for a total transaction of $40,500.22. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,926 shares of company stock valued at $2,782,523. 66.70% of the stock is owned by insiders.
TCDA has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Tricida from a “sell” rating to a “hold” rating in a report on Thursday, October 10th. Needham & Company LLC set a $50.00 price target on shares of Tricida and gave the stock a “buy” rating in a report on Monday, August 12th. ValuEngine upgraded shares of Tricida from a “sell” rating to a “hold” rating in a report on Friday, October 11th. Finally, Cowen set a $50.00 price target on shares of Tricida and gave the stock a “buy” rating in a report on Tuesday, October 15th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Tricida currently has an average rating of “Buy” and a consensus target price of $49.60.
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.